Association of a genetic variant of endothelial nitric oxide synthase with the 1 year clinical outcome after coronary stent placement

European Heart Journal

Volumn 24, Issue 9, 2003, Pages 820-827

  Gorchakova, Olga ^a   Koch, Werner ^a   Von Beckerath, Nicolas ^a   Mehilli, Julinda ^a   Schömig, Albert ^a   Kastrati, Adnan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Adverse outcome; Endothelial nitric oxide synthase; Genetics; Myocardial infarction; Restenosis; Stents

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ANGIOGRAPHY; ARTICLE; CONFIDENCE INTERVAL; CORONARY ARTERY DISEASE; CORONARY STENT; DEATH; EXON; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEART MUSCLE REVASCULARIZATION; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZATION; RESTENOSIS; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

ACUTE DISEASE; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CORONARY STENOSIS; CORONARY THROMBOSIS; CORONARY VASOSPASM; FEMALE; GENOTYPE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; RISK FACTORS; STENTS;

EID: 0037627724     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-668X(02)00824-2     Document Type: Article

References (49)

1. Nathan C, Xie Q-w. Nitric oxide synthases: roles, tolls, and controls. Cell 1994;78:915-8.
2. Lloyd-Jones DM, Bloch KD. The vascular biology of nitric oxide and its role in atherogenesis. Annu Rev Med 1996; 47:365-75.
3. Wever RMF, Lüscher TF, Cosentino F et al. Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation 1998;97:108-12.
4. Ignarro LJ. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu Rev Pharmacol Toxicol 1990;30:535-60.
5. Oemar BS, Tschudi MR, Godoy N et al. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation 1998;97:2494-8.
6. Keaney JF Jr, Vita JA. Atherosclerosis, oxidative stress, and antioxidant protection in endothelium-derived relaxing factor action. Prog Cardiovasc Dis 1995;38:129-54.
7. Nava E, Noll G, Lüscher TF. Nitric oxide in cardiovascular diseases. Ann Med 1995;27:343-51.
8. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-42.
9. Yoshimura M, Yasue H, Nakayama M et al. A missence Glu298 Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese. Hum Genet 1998;103:65-9.
10. 298→ Asp) is a major risk factor for coronary artery disease in the UK. Circulation 1999;100:1515-20.
11. Hibi K, Ishigami T, Tamura K et al. Endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction. Hypertension 1998;32:521-6.
12. Shimasaki Y, Yasue H, Yoshimura M et al. Association of the missence Glu298 Asp variant of the endothelial nitric oxide synthase gene with myocardial infarction. J Am Coll Cardiol 1998;31:1506-10.
13. Schömig A, Kastrati A, Mudra H et al. Four-year experience with Palmaz-Schatz stenting in coronary angioplasty complicated by dissection with threatened or present vessel closure. Circulation 1994;90:2716-24.
14. Schömig A, Neumann F-J, Kastrati A et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-9.
15. Livak KJ. Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal 1999;14:143-9.
16. Ellis SG, Vandormael MG, Cowley MJ et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel angioplasty prognosis study group. Circulation 1990;82:1193-202.
17. Rutherford JD, Braunwald E, Cohn PF. Chronic ischemic heart disease. In: Braunwald E, editor. Heart disease: a textbook of cardiovascular medicine. Philadelphia, PA: WB Saunders Company; 1988, p. 1314-78.
18. World Health Organization Study Group. Diabetes mellitus. World Health Organ Tech Rep Ser 1985;727:1-104.
19. Guidelines Subcommittee. 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999;17:151-83.
20. Markus HS, Ruigrok Y, Ali N et al. Endothelial nitric oxide synthase exon 7 polymorphism, ischemic cerebrovascular disease, and carotid atheroma. Stroke 1998;29:1908-11.
21. Cai H, Wilcken DEL, Wang XL. The glu-298 → asp (894G → T) mutation at exon 7 of the endothelial nitric oxide synthase gene and coronary artery disease. J Mol Med 1999; 77:511-4.
22. Poirier O, Mao C, Mallet C et al. Polymorphisms of the endothelial nitric oxide synthase gene-no consistent association with myocardial infarction in the ECTIM study. Eur J Clin Invest 1999;29:284-90.
23. Komatsu R, Ueda M, Naruko T et al. Neointimal tissue response at sites of coronary stenting in humans. Macroscopic, histological, and immunohistochemical analyses. Circulation 1998;98:224-33.
24. Farb A, Sangiorgi G, Carter AJ et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999;99:44-52.
25. Grewe PH, Deneke T, Machraoui A et al. Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen. J Am Coll Cardiol 2000;35:157-63.
26. Tesauro M, Thompson WC, Rogliani P et al. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci USA 2000;97:2832-5.
27. Moro MA, Russell RJ, Cellek S et al. cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci USA 1996;93:1480-5.
28. Freedman JE, Loscalzo J, Barnard MR et al. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest 1997;100:350-6.
29. Mak K-H, Belli G, Ellis SG et al. Subacute stent thrombosis: evolving issues and current concepts. J Am Coll Cardiol 1996;27:494-503.
30. Freedman JE, Ting B, Hankin B et al. Impaired platelet production of nitric oxide predicts presence of acute coronary syndromes. Circulation 1998;98:1481-6.
31. Takajo Y, Ikeda H, Haramaki N et al. Augmented oxidative stress of platelets in chronic smokers: mechanisms of impaired platelet-derived nitric oxide bioactivity and augmented platelet aggregability. J Am Coll Cardiol 2001;38:1320-7.
32. Kanaya S, Ikeda H, Haramaki N et al. Intraplatelet tetrahydrobiopterin plays an important role in regulating canine coronary arterial thrombosis by modulating intraplatelet nitric oxide and superoxide generation. Circulation 2001;104:2478-84.
33. Schömig A, Neumann F-J, Walter H et al. Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. J Am Coll Cardiol 1997;29:28-34.
34. The EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92.
35. Lincoff AM, Tcheng JE, Califf RM et al., for the EPILOG Investigators. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab. Circulation 1999;99:1951-8.
36. Kastrati A, Schömig A, Elezi S et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997;30:1428-36.
37. Schömig A, Kastrati A, Elezi S et al. Bimodal distribution of angiographic measures of restenosis six months after coronary stent placement. Circulation 1997;96:3880-7.
38. Bauters C, Hubert E, Prat A et al. Predictors of restenosis after coronary stent implantation. J Am Coll Cardiol 1998;31:1291-8.
39. Kastrati A, Schömig A, Elezi S et al. Prognostic value of the modified American College of Cardiology/American Heart Association stenosis morphology classification for long-term angiographic and clinical outcome after coronary stent placement. Circulation 1999;100:1285-90.
40. A polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation 1999;99:1005-10.
41. Kastrati A, Schömig A, Dirschinger J et al. Increased risk of restenosis after placement of gold-coated stents: results of a randomized trial comparing gold-coated with uncoated steel stents in patients with coronary artery disease. Circulation 2000;101:2478-83.
42. Kastrati A, Koch W, Berger PB et al. Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. J Am Coll Cardiol 2000;36:2168-73.
43. Kastrati A, Mehilli J, Dirschinger J et al. Restenosis after coronary placement of various stent types. Am J Cardiol 2001;87:34-9.
44. Koch W, Böttiger C, Mehilli J et al. Association of a CD18 gene polymorphism with a reduced risk of restenosis after coronary stenting. Am J Cardiol 2001;88:1120-4.
45. Kastrati A, Mehilli J, Dirschinger J et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (Isar-Stereo) trial. Circulation 2001;103:2816-21.
46. Kastrati A, Schömig A, Dietz R et al. Time course of restenosis during the first year after emergency coronary stenting. Circulation 1993;87:1498-505.
47. Murad F. What are the molecular mechanisms for the antiproliferative effects of nitric oxide and cGMP in vascular smooth muscle? Circulation 1997;95:1101-3.
48. Yu S-M, Hung L-M, Lin C-C. cGMP-elevating agents suppress proliferation of vascular smooth muscle cells by inhibiting the activation of epidermal growth factor signaling pathway. Circulation 1997;95:1269-77.
49. Schwartz RS. Pathophysiology and restenosis: interaction of thrombosis, hyperplasia, and/or remodeling. Am J Cardiol 1998;81:14E-17E.